POSC399 Treatment Effect and Costs of the Complete Therapeutic Pathway in Patients with First-Line Castration-Resistant Prostate Cancer with Either First-Line Docetaxel or Abiraterone Acetate Plus Prednisone
Abstract
Authors
MS Holleman I Santi S Huygens KKH Aben ACM Van den Bergh AM Bergman AJM van den Eertwegh MCP Kuppen J Lavalaye NM Mehra RJA van Moorselaar IM Van Oort DM Somford HM Westgeest WR Gerritsen CA Uyl-De Groot